Form 13-F position report

CUE BIOPHARMA INC

Reported by STIFEL FINANCIAL CORP

CUE CUSIP 22978P106 Manager CIK 0000720672

Reported 193,990 shares, up 1,398 (0.7%) from the prior quarter.

Reported value -33.9%; share count 0.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 193,990 Quarter-end amount reported
Reported value $240,546 Fair value at quarter end
Consecutive quarters held 21 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 754000
2022-03-31 325000
2022-06-30 165000
2022-09-30 148000
2022-12-31 371538
2023-03-31 522879
2023-06-30 537722
2023-09-30 338592
2023-12-31 512095
2024-03-31 364001
2024-06-30 240546
2024-09-30 147067
2024-12-31 230383
2025-03-31 185460
2025-06-30 134110
2025-09-30 141265
2025-12-31 75298
2026-03-31 56683
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for CUE BIOPHARMA INC held by STIFEL FINANCIAL CORP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -246,556 (-100.0%) 0 $0 2026-08-12
Q1 2026 Unchanged 246,556 0 (0.0%) < 0.01% $56,683 2026-05-12
Q4 2025 Added 246,556 +50,000 (25.4%) < 0.01% $75,298 2026-02-13
Q3 2025 Unchanged 196,556 0 (0.0%) < 0.01% $141,265 2025-11-12
Q2 2025 Reduced 196,556 -7,022 (-3.4%) < 0.01% $134,110 2025-08-14
Q1 2025 Reduced 203,578 -7,783 (-3.7%) < 0.01% $185,460 2025-05-14
Q4 2024 Added 211,361 +17,139 (8.8%) < 0.01% $230,383 2025-02-13
Q3 2024 Added 194,222 +232 (0.1%) < 0.01% $147,067 2024-11-14
Q2 2024 Added 193,990 +1,398 (0.7%) < 0.01% $240,546 2024-08-13
Q1 2024 Reduced 192,592 -1,383 (-0.7%) < 0.01% $364,001 2024-05-14
Q4 2023 Added 193,975 +46,763 (31.8%) < 0.01% $512,095 2024-02-12
Q3 2023 Reduced 147,212 -109 (-0.1%) < 0.01% $338,592 2023-11-13
Q2 2023 Added 147,321 +857 (0.6%) < 0.01% $537,722 2023-08-14
Q1 2023 Added 146,464 +16,101 (12.4%) < 0.01% $522,879 2023-05-12
Q4 2022 Added 130,363 +63,707 (95.6%) < 0.01% $371,538 2023-02-13
Q3 2022 Unchanged 66,656 0 (0.0%) < 0.01% $148,000 2022-11-14
Q2 2022 Unchanged 66,656 0 (0.0%) < 0.01% $165,000 2022-08-15
Q1 2022 Unchanged 66,656 0 (0.0%) < 0.01% $325,000 2022-05-13
Q4 2021 Added 66,656 +770 (1.2%) < 0.01% $754,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

97 managers reported CUE BIOPHARMA INC for Q2 2024.

Managers reporting CUE BIOPHARMA INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Bleichroeder LP Added 2,861,606 +106,578 1.06% $3,548,391 19 qtrs
Slate Path Capital LP Unchanged 2,402,455 0 0.06% $2,979,044 20 qtrs
VANGUARD GROUP INC Reduced 2,031,421 -251,941 < 0.01% $2,518,962 26 qtrs
BlackRock Inc Reduced 756,736 -1,487,367 < 0.01% $938,353 26 qtrs
MILLENNIUM MANAGEMENT LLC Added 493,987 +131,897 < 0.01% $612,544 17 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 492,456 -346,075 < 0.01% $610,794 26 qtrs
Robertson Stephens Wealth Management LLC Unchanged 478,500 0 0.03% $593,340 16 qtrs
NORTHERN TRUST CORPORATION Reduced 350,419 -14,763 < 0.01% $434,519 26 qtrs
Good Life Advisors LLC Added 325,000 +225,000 0.03% $403,001 9 qtrs
GSA CAPITAL PARTNERS LLP Added 277,559 +68,459 0.02% $344,000 16 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 13, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
193,990
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.